Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy
and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fasting
conditions.